Additional testing completed on Alzheimer's disease biomarker
Navidea has announced completion of tests into the impact of mass doses of its NAV4694 biomarker on PET scans of patients with Alzheimer's.
Biopharma company Navidea Biopharmaceuticals has announced the completion of a study into its new radiopharmaceutical NAV4694, which is designed to be used as a biomarker for visual detection of substances used in the diagnosis of Alzheimer's disease.
The study was designed by partner firm AstraZeneca to assess the effects that different amounts of the biomarker have on the safety and efficacy of Positron Emission Tomography (PET) scanning in patients with the neuro-degenerative condition.
Comparing patients to health controls, evaluations were completed on two mass doses of the radiogland and the effects they had on image quality.
"We are very pleased to have completed this study addressing some of the fundamental requirements of diagnostic imaging agents seeking approval," said Cornelia Reininger, managing director of Navidea and the company's chief medical officer.
"We continue to make exciting progress with NAV4694, which has demonstrated important performance characteristics that we believe position it as a true 'best-in-class' second generation agent to aid in the diagnosis of Alzheimer's disease."
Related News
-
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. -
Sponsored Content CPHI Online Trend Report: How can flow chemistry help businesses achieve their sustainability goals?
In our latest CPHI Online Trend Report, we partner with Asymchem to understand the innovative potential of flow chemistry for API manufacturing, especially in regards to meeting sustainability goals.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance